<p>根据 S&amp;P 全球市场情报的数据，<strong>Hims &amp; Hers</strong>(HIMS 1.74%) 的股票本周下跌了 17%。该远程医疗平台正在实现巨大的收入增长，但面临与减肥药制造商的法律纠纷风险。该股票的价格比历史最高点下跌了 25%，但由于平台的快速增长，过去五年上涨了 400%。</p>
<p>以下是本周股票下跌的原因。</p>
<h2>快速增长但面临诉讼</h2>
<p>在 2025 年第二季度，Hims &amp; Hers 的收入同比增长 73%，超过 5 亿美元，使其成为全球增长最快的公司之一。这得益于 Hims &amp; Hers 产品的总订阅用户增长 30% 以及每位活跃用户的消费增长 30%。该公司提供基本药品的远程医疗服务，如脱发、性健康和减肥药。</p>
<p>尽管公司快速增长并且现在实现了盈利，但 Hims &amp; Hers 正面临与 <strong>诺和诺德</strong> 的法律纠纷。减肥药的创新者最初与 Hims &amp; Hers 建立了合作关系，但因对 Hims &amp; Hers 销售其减肥药配方的仿制品存在分歧而退出了交易。Hims &amp; Hers 在短缺期间被允许销售专利减肥药，但现在短缺已结束，销售专利药物给客户并提供折扣的行为已违反法律。</p>
<p>毫不奇怪，Hims &amp; Hers 因这一做法而被起诉，而这一做法正是其业务快速增长的一部分。投资者对这场法律纠纷的未来影响感到担忧，担心这可能会损害 Hims &amp; Hers 未来的收入增长和盈利能力。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>你应该购买 Hims &amp; Hers 的股票吗？</h2>
<p>在过去几年中，Hims &amp; Hers 的股票表现出色，使股东们获得了丰厚的回报。它的收入达到 20 亿美元，过去五年增长超过 1000%。毫无疑问，它是互联网药物和医疗治疗的领先远程医疗提供商，在过去几年中在市场份额上取得了巨大的进展。</p>
<p>如果没有法律纠纷，Hims &amp; Hers 可能会在这次下跌中成为一个值得购买的股票。然而，我们不能忽视潜在的法律后果以及 Hims &amp; Hers 管理层通过公然在其网站上销售专利减肥药而给自己和股东带来的巨大风险。这场法律纠纷不太可能有好的结果。在与减肥药制造商的争端解决之前，不要在 Hims &amp; Hers 的股票上抄底。</p>

HIMS

<p>Hims & Hers 的股票本周下跌了 17%，较历史最高点下跌了 25%，尽管 2025 年第二季度的收入增长达 73%。该远程医疗平台正面临与 Novo Nordisk 的法律纠纷，涉及销售专利减肥药物，这引发了对未来收入和盈利能力的担忧。尽管公司经历了显著增长，但建议投资者在法律问题解决之前不要购买该股票，因为这些问题对其业务构成了重大风险</p>

<p>Shares of <strong>Hims &amp; Hers</strong>(HIMS 1.74%) stock sank 17% this week, according to data from S&amp;P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers. Shares of the stock are down 25% from all-time highs but are up 400% in the past five years due to the platform's fast growth.</p>
<div class="lb-trans"><p>根据 S&amp;P 全球市场情报的数据，<strong>Hims &amp; Hers</strong>(HIMS 1.74%) 的股票本周下跌了 17%。该远程医疗平台正在实现巨大的收入增长，但面临与减肥药制造商的法律纠纷风险。该股票的价格比历史最高点下跌了 25%，但由于平台的快速增长，过去五年上涨了 400%。</p>
</div><p>Here's why the stock sank this week.</p>
<div class="lb-trans"><p>以下是本周股票下跌的原因。</p>
</div><h2>Fast growth but a looming lawsuit</h2>
<div class="lb-trans"><h2>快速增长但面临诉讼</h2>
</div><p>In the second quarter of 2025, Hims &amp; Hers' revenue grew 73% year over year to over $500 million, making it one of the fastest-growing companies in the world. This was driven by 30% growth in total subscribers to Hims &amp; Hers products and 30% growth in spend per active subscriber. The company offers telehealth services for basic pharmaceuticals such as hair loss, sexual wellness, and weight loss drugs.</p>
<div class="lb-trans"><p>在 2025 年第二季度，Hims &amp; Hers 的收入同比增长 73%，超过 5 亿美元，使其成为全球增长最快的公司之一。这得益于 Hims &amp; Hers 产品的总订阅用户增长 30% 以及每位活跃用户的消费增长 30%。该公司提供基本药品的远程医疗服务，如脱发、性健康和减肥药。</p>
</div><p>While the company is growing quickly and now generating a profit, Hims &amp; Hers is facing a looming legal battle with <strong>Novo Nordisk</strong>. The innovator in weight loss drugs originally had a partnership with Hims &amp; Hers but pulled out of the deal because of disagreements over Hims &amp; Hers selling knockoffs of its weight loss drug formula. Hims &amp; Hers was permitted to sell patented weight loss drugs while they were in shortage, but now that the shortage is over, it is breaking the law by selling patented drugs to customers at a discount.</p>
<div class="lb-trans"><p>尽管公司快速增长并且现在实现了盈利，但 Hims &amp; Hers 正面临与 <strong>诺和诺德</strong> 的法律纠纷。减肥药的创新者最初与 Hims &amp; Hers 建立了合作关系，但因对 Hims &amp; Hers 销售其减肥药配方的仿制品存在分歧而退出了交易。Hims &amp; Hers 在短缺期间被允许销售专利减肥药，但现在短缺已结束，销售专利药物给客户并提供折扣的行为已违反法律。</p>
</div><p>Unsurprisingly, Hims &amp; Hers is getting sued for this practice, which is a fast-growing part of its business. Investors are worried about the future impacts of this legal battle and how it could hurt Hims &amp; Hers' future revenue growth and profitability.</p>
<div class="lb-trans"><p>毫不奇怪，Hims &amp; Hers 因这一做法而被起诉，而这一做法正是其业务快速增长的一部分。投资者对这场法律纠纷的未来影响感到担忧，担心这可能会损害 Hims &amp; Hers 未来的收入增长和盈利能力。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828726%2Fhealthcare.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>Should you buy Hims &amp; Hers stock?</h2>
<div class="lb-trans"><h2>你应该购买 Hims &amp; Hers 的股票吗？</h2>
</div><p>Hims &amp; Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in trailing revenue, up over 1,000% in the last five years. By far, it is the leading telehealth provider for drugs and medical treatments over the internet, making a ton of inroads in market share gains in the last few years.</p>
<div class="lb-trans"><p>在过去几年中，Hims &amp; Hers 的股票表现出色，使股东们获得了丰厚的回报。它的收入达到 20 亿美元，过去五年增长超过 1000%。毫无疑问，它是互联网药物和医疗治疗的领先远程医疗提供商，在过去几年中在市场份额上取得了巨大的进展。</p>
</div><p>If there were no legal battle looming, Hims &amp; Hers would probably be a buy on this dip. However, we cannot ignore the potential legal ramifications and <em>huge risk</em> Hims &amp; Hers management is putting on itself and shareholders by blatantly selling patented weight loss drugs on its website. This legal battle is not likely to end well. Don't buy the dip on Hims &amp; Hers stock until its dispute with the weight loss drugmakers is resolved.</p>
<div class="lb-trans"><p>如果没有法律纠纷，Hims &amp; Hers 可能会在这次下跌中成为一个值得购买的股票。然而，我们不能忽视潜在的法律后果以及 Hims &amp; Hers 管理层通过公然在其网站上销售专利减肥药而给自己和股东带来的巨大风险。这场法律纠纷不太可能有好的结果。在与减肥药制造商的争端解决之前，不要在 Hims &amp; Hers 的股票上抄底。</p>
</div>

为什么 Hims & Hers Health 的股票本周下跌